Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Novo Nordisk says Victoza helps lower heart risks

Novo Nordisk said on Friday the results from a trial showed that its Victoza diabetes drug significantly reduced the risks of major adverse cardiovascular events.   “People with type 2 diabetes generally have a higher risk of experiencing major adverse cardiovascular events. That’s why we are very excited about the results from LEADER (trial), which […]

Read More »

Regular Aspirin Use Cuts Overall Cancer Risk, Massachusetts General Hospital Study

Aspirin Found To Reduce Overall Cancer Risk An analysis of data from two long-term epidemiologic studies has found that regular use of aspirin significantly reduces the overall risk of cancer, an effect that primarily reflects a lower risk of colorectal cancer and other tumors of the gastrointestinal tract. The findings, published in JAMA Oncology, suggest […]

Read More »

Amgen Aggressively Challenges Pfizer and Novartis AG Biosimilar Drugs

THOUSAND OAKS, Calif. – Amgen (AMGN) is in for a long fight as the company fights to protect its patents from biosimilar drugs that threaten a significant portion of the company revenues, bidnessetc reported this morning. Four of Amgen’s drugs are facing the threat of biosimilar drugs, including the cancer drug Neupogen, which is used […]

Read More »

Video games, social media tied to shorter sleep for teens

<span class="articleLocation”>(Reuters Health) – Teens who play video games before bedtime go to bed later and those who use online social media take longer to fall asleep, according to a recent study. These technology-related behaviors were tied to shorter and poorer sleep for teens on school days and even on vacation, while kids who stuck […]

Read More »

Generic drug ETF ailing despite political focus on high drug prices

Calls in the U.S. presidential campaign to cut pharmaceutical prices are not helping to revive a barely two-month-old exchange-traded fund that invests in shares of generic drugmakers. In fact, low prices that define generic drugs may be the ETF’s biggest stumbling block, analysts said this week. The Market Vectors Generic Drugs ETF, which fund manager […]

Read More »

Obama Administration Hits Medicare Payment Target Early

By Louise Radnofsky Louise Radnofsky The Wall Street Journal CANCEL Biography @louiseradnofsky Google+ March 3, 2016 4:25 p.m. ET 32 COMMENTS WASHINGTON—Obama administration officials said Thursday they were almost a year ahead of their target to change the way Medicare pays hundreds of billions of dollars to providers for treating older Americans. The Department of Health […]

Read More »

Evoke Health Announces Creation of Evoke Group

‘FIRSTHAND’ and ‘Traverse HealthStrategy’ join ‘Evoke Health’ in Pursuit of a More Human Health Experience for Customers.   March 1, 2016 (New York) – Evoke Health, one of the world’s largest consumer health and wellness agencies, today announced the creation of FIRSTHAND, a new digital marketing agency, and Traverse HealthStrategy, a digital health consultancy. The […]

Read More »

Endo to flag Opana ER painkiller’s risks, under NY settlement

Endo International Plc agreed to stop marketing its Opana ER painkiller pill as crush-resistant, and stop downplaying the risks of addiction associated with the narcotic, under a settlement with New York state announced on Thursday. The company will also pay a $200,000 penalty. State Attorney General Eric Schneiderman said Endo’s own studies found that the […]

Read More »

Giant names new senior VP, executive creative director

SAN FRANCISCO, MARCH 2, 2016–Giant Creative/Strategy, LLC, the largest full-service independent healthcare communications agency on the West Coast, recently named Joshua McCasland to SVP, Executive Creative Director.  In his new position, McCasland plays a pivotal role in helping his team develop creative work for clients that results in measurable customer engagement while effectively telling unified brand narratives across multiple […]

Read More »

Led By Ex-Sanofi Exec, Mysterious Ribon Therapeutics Eyes a New Type of Cancer Drug

March 3, 2016 By Alex Keown, Breaking News Staff   BOSTON – Ribon Therapeutics is a stealthy and privately-held startup focused on developing therapeutics targeting poly ADP-ribose polymerase (PARPs) for cancer. But other than that, little is known about the company that was founded in 2015. Its website contains no information, other than the […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom